Takeda Oncology
Nicholas Ferenc is an experienced professional in the oncology sector, currently serving as Global Project Leader in R&D at Takeda Oncology since 2020, and previously holding the position of Senior Director in Portfolio Management and External Innovation at Takeda Pharmaceuticals since January 2014. With a robust background in personalized medicine and companion diagnostics strategy at Sanofi, Nicholas developed critical functions within the oncology division, overseeing CDx strategy and development. Additional accomplishments include leading global marketing efforts for Thymoglobulin, achieving significant sales growth, and holding various strategic roles at companies such as Wyeth and AstraZeneca. Nicholas holds a Master of Science in Molecular Biology/Biotechnology and an MBA from The Johns Hopkins University, in addition to a BS in Chemistry from Wake Forest University.
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.